AEON Biopharma reported strong progress in Q1 2026, receiving positive FDA feedback on its ABP-450 biosimilar analytical strategy under the 351(k) pathway. The company significantly reduced its debt by over 90% through financing and note exchanges, strengthening its balance sheet. AEON plans a Type 2b FDA meeting later in 2026 to discuss further development steps toward full-label approval of ABP-450, aiming to compete in the $3 billion U.S. therapeutic neurotoxin market. Cash reserves support operations into Q3 2026, with upcoming scientific presentations and shareholder meetings scheduled.
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Ethereum rose 3.17% to $1,923.53, outperforming Bitcoin's modest 0.18% gain to $64,588.87, signaling an early rotation toward large-cap altcoins. Despite this, overall market activity slowed, with declines in DeFi, stablecoin, and derivatives trading...
Gabriel Holding A/S has agreed to sell its European FurnMaster furniture manufacturing operations, including subsidiaries in Poland and Lithuania, to Leggett & Platt for an initial price of approximately EUR 9 million, with a possible additional paym...
A Gaza resident raised over £55,000 on GoFundMe to support his family but faced issues as the platform cannot pay directly to Gaza, forcing funds through intermediaries who failed to deliver the full amount. This highlights a broader problem in human...
Crypto investigator ZachXBT criticized all current hardware wallets as insecure and unreliable for signing transactions or storing significant funds. He highlighted Ledger as particularly problematic due to frequent updates that disrupt basic functio...
